<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cannabinoid Research References</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            max-width: 800px;
            margin: 0 auto;
            padding: 20px;
            min-height: 100vh;
            background: linear-gradient(160deg, #f0f4f8, #e0e9f2);
            overflow-x: hidden;
        }

        .container {
            background-color: rgba(255, 255, 255, 0.98);
            padding: 30px;
            border-radius: 10px;
            box-shadow: 0 0 15px rgba(0,0,0,0.1);
            position: relative;
            z-index: 1;
        }

        .title {
            text-align: center;
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            color: #2c5e3a;
            font-size: 2.5rem;
            margin: 1rem 0 2rem;
            letter-spacing: 1.5px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.1);
            position: relative;
            padding-bottom: 1rem;
        }

        .title::after {
            content: '';
            position: absolute;
            width: 60px;
            height: 3px;
            background: #3d7a4b;
            bottom: 0;
            left: 50%;
            transform: translateX(-50%);
            border-radius: 2px;
        }

        .title:hover {
            color: #245832;
            text-shadow: 2px 2px 6px rgba(0,0,0,0.15);
            transition: all 0.3s ease;
        }

        .pill {
            position: fixed;
            animation: pill-fall 6s linear infinite;
            pointer-events: none;
            z-index: 2;
            filter: drop-shadow(2px 2px 3px rgba(0,0,0,0.2));
        }

        @keyframes pill-fall {
            0% {
                transform: translateY(-100vh) translateX(-10vw) rotate(0deg);
                opacity: 0.9;
            }
            100% {
                transform: translateY(100vh) translateX(10vw) rotate(720deg);
                opacity: 0;
            }
        }

        .reference {
            margin-bottom: 25px;
            padding: 20px;
            border-left: 4px solid #3d7a4b;
            background-color: rgba(248, 249, 250, 0.95);
            transition: transform 0.3s ease;
        }

        .reference:hover {
            transform: translateX(5px);
        }
    </style>
</head>
<body>
    <div class="container">
        <h1 class="title">Cannabinoid Research References</h1>
        <div class="references">
            <!-- Reference 1 -->
            <div class="reference" id="ref1">
                <h3>[1] García C, et al. (2016)</h3>
                <p><em>Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia</em></p>
                <p>British Journal of Pharmacology 173(13):2069-2079</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1111/bph.13215" target="_blank">10.1111/bph.13215</a></p>
            </div>

            <!-- Reference 2 -->
            <div class="reference" id="ref2">
                <h3>[2] Patricio F, et al. (2020)</h3>
                <p><em>Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease</em></p>
                <p>Frontiers in Pharmacology 11</p>
                <p class="doi">DOI: <a href="https://doi.org/10.3389/fphar.2020.595635" target="_blank">10.3389/fphar.2020.595635</a></p>
            </div>

            <!-- Reference 3 -->
            <div class="reference" id="ref3">
                <h3>[3] Cooray R, et al. (2020)</h3>
                <p><em>Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: a review</em></p>
                <p>Molecular Neurobiology 57(8):4878-4890</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1007/s12035-020-02054-6" target="_blank">10.1007/s12035-020-02054-6</a></p>
            </div>

            <!-- Reference 4 -->
            <div class="reference" id="ref4">
                <h3>[4] Stampanoni Bassi M, et al. (2017)</h3>
                <p><em>Cannabinoids in Parkinson’s disease</em></p>
                <p>Cannabis and Cannabinoid Research 2(1):21-29</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1089/can.2017.0002" target="_blank">10.1089/can.2017.0002</a></p>
            </div>

            <!-- Reference 5 -->
            <div class="reference" id="ref5">
                <h3>[5] Ye L, et al. (2019)</h3>
                <p><em>New Insights in Cannabinoid Receptor Structure and Signaling</em></p>
                <p>Current Molecular Pharmacology 12(3):239-248</p>
                <p class="doi">DOI: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6864585/" target="_blank">10.2174/1874467212666190215112036</a></p>
            </div>

            <!-- Reference 6 -->
            <div class="reference" id="ref6">
                <h3>[6] de Almeida DL, Devi LA. (2020)</h3>
                <p><em>Diversity of molecular targets and signaling pathways for CBD</em></p>
                <p>Pharmacology Research & Perspectives 8(6):e00682</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1002/prp2.682" target="_blank">10.1002/prp2.682</a></p>
            </div>

            <!-- Reference 7 -->
            <div class="reference" id="ref7">
                <h3>[7] Wi R, et al. (2020)</h3>
                <p><em>Functional crosstalk between CB and TRPV1 receptors protects nigrostriatal dopaminergic neurons in the MPTP model of Parkinson’s disease</em></p>
                <p>Journal of Immunology Research 2020:5093493</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1155/2020/5093493" target="_blank">10.1155/2020/5093493</a></p>
            </div>

            <!-- Reference 8 -->
            <div class="reference" id="ref8">
                <h3>[8] Giuliano C, et al. (2021)</h3>
                <p><em>Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease</em></p>
                <p>International Journal of Molecular Sciences 22(16):8920</p>
                <p class="doi">DOI: <a href="https://doi.org/10.3390/ijms22168920" target="_blank">10.3390/ijms22168920</a></p>
            </div>

            <!-- Reference 9 -->
            <div class="reference" id="ref9">
                <h3>[9] García C, et al. (2011)</h3>
                <p><em>Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease</em></p>
                <p>British Journal of Pharmacology 163(7):1495–1506</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1111/j.1476-5381.2011.01278.x" target="_blank">10.1111/j.1476-5381.2011.01278.x</a></p>
            </div>

            <!-- Reference 10 -->
            <div class="reference" id="ref10">
                <h3>[10] Peball M, et al. (2020)</h3>
                <p><em>Non-motor symptoms in Parkinson’s disease are reduced by nabilone</em></p>
                <p>Annals of Neurology 88(4):712-722</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1002/ana.25864" target="_blank">10.1002/ana.25864</a></p>
            </div>

            <!-- Reference 11 -->
            <div class="reference" id="ref11">
                <h3>[11] Viveros-Paredes JM, et al. (2019)</h3>
                <p><em>Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage</em></p>
                <p>Neurología 34(3):143-152</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1016/j.nrl.2016.11.003" target="_blank">10.1016/j.nrl.2016.11.003</a></p>
            </div>

            <!-- Reference 12 -->
            <div class="reference" id="ref12">
                <h3>[12] Ren S, et al. (2020)</h3>
                <p><em>Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors</em></p>
                <p>Acta Pharmacologica Sinica 41(10):1263-1271</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1038/s41401-020-0385-7" target="_blank">10.1038/s41401-020-0385-7</a></p>
            </div>
            
            <!-- Reference 13 -->            
            <div class="reference" id="ref13">
                <h3>[13] More SV, Choi DK. (2015)</h3>
                <p><em>Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection</em></p>
                <p>Molecular Neurodegeneration 10:17</p>
                <p class="doi">DOI: <a href="https://doi.org/10.1186/s13024-015-0012-0" target="_blank">10.1186/s13024-015-0012-0</a></p>
            </div>
            
            <!-- Reference 14 -->
            <div class="reference" id="ref14">
                <h3>[14] Sousa A, DiFrancisco-Donoghue J. (2023)</h3>
                <p><em>Cannabidiol and Tetrahydrocannabinol Use in Parkinson's Disease: An Observational Pilot Study</em></p>
                <p>Cureus 15(7):e42391</p>
                <p class="doi">DOI: <a href="https://doi.org/10.7759/cureus.42391" target="_blank">10.7759/cureus.42391</a></p>
            </div>
            
            <!-- Reference 15 -->
            <div class="reference" id="ref15">
                <h3>[15] Basile MS, Mazzon E. (2022)</h3>
                <p><em>The Role of Cannabinoid Type 2 Receptors in Parkinson's Disease</em></p>
                <p>Biomedicines 10(11):2986</p>
                <p class="doi">DOI: <a href="https://doi.org/10.3390/biomedicines10112986" target="_blank">10.3390/biomedicines10112986</a></p>
            </div>
            
            <!-- Reference 16 -->
            <div class="reference" id="ref16">
                <h3>[16] Vuic B, et al. (2022)</h3>
                <p><em>Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential</em></p>
                <p>Biomedicines 10(12):3000</p>
                <p class="doi">DOI: <a href="https://doi.org/10.3390/biomedicines10123000" target="_blank">10.3390/biomedicines10123000</a></p>
            </div>
        </div>
    </div>

<!-- Animated Background Elements -->
    
   <script>
        (function() {
            'use strict';
            
            const pillShapes = [
                // Capsule
                '<rect x="6" y="2" width="12" height="20" rx="6" fill="#007bff" stroke="#000"/>',
                // Round pill
                '<circle cx="12" cy="12" r="8" fill="#dc3545" stroke="#000"/>'
            ];

            function createPill() {
                const pill = document.createElementNS("http://www.w3.org/2000/svg", "svg");
                pill.setAttribute("viewBox", "0 0 24 24");
                pill.style.width = `${30 + Math.random() * 30}px`;
                pill.style.left = `${Math.random() * 100}%`;
                pill.style.animationDuration = `${4 + Math.random() * 4}s`;
                pill.classList.add('pill');
                pill.innerHTML = pillShapes[Math.floor(Math.random() * pillShapes.length)];
                document.body.appendChild(pill);

                // Remove after animation
                setTimeout(() => pill.remove(), (4 + Math.random() * 4) * 1000);
            }

            // Start animation
            function init() {
                setInterval(createPill, 800);
                createPill(); // Initial pill
            }

            window.addEventListener('load', init);
        })();
    </script>
</body>
</html>
